Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Thérese Sørlie, Charles M. Perou, Robert Tibshirani et al. · Proceedings of the National Academy of Sciences · 2001 · 10.9K citations · Full text

Medicine, Molecular Biology, Oncology +16

A Gene-Expression Signature as a Predictor of Survival in Breast Cancer

Marc J. van de Vijver, Yudong D. He, Laura van ‘t Veer et al. · New England Journal of Medicine · 2002 · 6.5K citations · Full text

Medicine, Bioinformatics, Oncology +17

Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer

Soonmyung Paik, Gong Tang, Steven Shak et al. · Journal of Clinical Oncology · 2006 · 2.6K citations

Medicine, Cancer Biology, Oncology +17

The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

Lisa A. Carey, Elizabeth Claire Dees, Lynda Sawyer et al. · Clinical Cancer Research · 2007 · 2.1K citations · Full text

Medicine, Oncology, Breast Oncology +14

Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

Roman Rouzier, Charles M. Perou, W. Fraser Symmans et al. · Clinical Cancer Research · 2005 · 1.9K citations · Full text

Medicine, Cancer Biology, Oncology +17